Development, characterization, and evaluation of a fusion protein of a novel glucagon-like peptide-1 (GLP-1) analog and human serum albumin in pichia pastoris

Bioscience, Biotechnology and Biochemistry

Volumn 73, Issue 3, 2009, Pages 688-694

  Gao, Zhihui ^a   Bai, Gang ^a   Chen, Jiaqi ^a   Zhang, Qi ^a   Pan, Pengwei ^a   Bai, Fang ^a   Geng, Peng ^a  

^a NANKAI UNIVERSITY   (China)

Author keywords

Diabetes; Fusion protein; Glucagons like peptide 1 analog; Human serum albumin; Immunomagnetic separation technique

Indexed keywords

DIABETES; FUSION PROTEIN; GLUCAGONS-LIKE PEPTIDE-1 ANALOG; HUMAN SERUM ALBUMIN; IMMUNOMAGNETIC SEPARATION TECHNIQUE;

AMINES; AMINO ACIDS; BODY FLUIDS; CHROMATOGRAPHIC ANALYSIS; DESORPTION; HIGH PRESSURE LIQUID CHROMATOGRAPHY; INDUSTRIAL LABORATORIES; IONIZATION OF LIQUIDS; MAGNETIC SEPARATORS; MASS SPECTROMETRY; PURIFICATION; SEPARATION;

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE RECEPTOR; GLUCOSE; HYBRID PROTEIN; INSULIN; SERUM ALBUMIN;

ANIMAL; ARTICLE; BIOSYNTHESIS; GENE EXPRESSION; GENETICS; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MOUSE; PICHIA; PROTEIN STABILITY; SECRETION;

ANIMALS; ANTIGENS, CD26; GENE EXPRESSION; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HUMANS; INSULIN; MICE; PICHIA; PROTEIN STABILITY; RECEPTORS, GLUCAGON; RECOMBINANT FUSION PROTEINS; SERUM ALBUMIN;

PICHIA PASTORIS;

EID: 65349102942     PISSN: 09168451     EISSN: 13476947     Source Type: Journal    
DOI: 10.1271/bbb.80742     Document Type: Article

References (40)

1. Kieffer, T. J., and Habener, J. F., The glucagons-like peptides. Endocr. Rev., 20, 876-913 (1999).
2. Hoist, J. J., Glucagon-like peptide-1 (GLP-1): an intestinal hormone, signaling nutritional abundance, with an unusual therapeutic potential. Trends Endocrinol. Metab., 10, 229-235 (1999).
3. Hui, H., Zhao, X., and Perfetti, R., Structure and function studies of glucagons-like peptide-1 (GLP-1): the designing of a novel pharmacological agent for the treatment of diabetes. Diabetes Metab. Res. Rev., 21, 313-331 (2005).
4. Nathan, D. M., Schreiber, E., Fogel, H., Mojsov, S., and Habener, J. F., Insulinotropic action of glucagons-like peptide-1(7-37) stimulation of proinsulin gene expression and proinsu-lin biosynthesis in insulinoma ß TC-1 cells. Diabetes Care, 130, 159-166 (1992).
5. Weir, G. C, Mojsov, S., Hendrick, G. K., and Habener, J. F., Glucagon-like peptide-1(7-37) action on endocrine pancreas. Diabetes, 38, 338-342 (1989).
6. Deacon, C. F., Johnsen, A. H., and Hoist, J. J., Degradation of glucagons-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab., 80, 952-957 (1995).
7. Burcelin, R., Dolci, W., and Thorens, B., Long-lasting anti-diabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagons-like peptide-1. Metabolism, 48, 252-258 (1999).
8. Gallwitz, B., Ropeter, T., Morys-Wortmann, C, Mentlein, R., Siegel, E. G., and Schmidt, W. E., GLP-1 analogues resistant to degradation by dipeptidyl-peptidase IV in vitro. Regul. Pept., 86, 103-111 (2000).
9. Deacon, C. F., Therapeutic strategic based on glucagons-like peptide-1. Diabetes, 53, 2181-2189 (2004).
10. Sudre, B., Broqua, P., White, R. B., Ashworth, D., Evans, D. M., Haigh, R., Junien, J. L., and Aubert, M. L., Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999 011 delays the occurrence of diabetes in male Zucker diabetic fatty rats. Diabetes, 51, 1461-1469 (2002).
11. Meier, J. J., Nauck, M. A., Kranz, D., Hoist, J. J., Deacon, C. F., Gaeckler, D., Schmidt, W. E., and Gallwitz, B., Secretion, degradation and elimination of glucagon-like peptide-1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes, 53, 654-662 (2004).
12. Hoist, J. J., Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia, 49, 253-260 (2006).
13. Chuang, V. T., Kragh-Hansen, U., and Otagiri, M., Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm. Res., 19, 569-577 (2002).
14. Koehler, M. F., Zobel, K., Beresini, M. H., Caris, L. D., Combs, D., Paasch, B. D., and Lazarus, R. A., Albumin affinity tags increase peptide half-life in vivo. Bioorg. Med. Chem. Lett., 12, 2883-2886 (2002).
15. Dennis, M. S., Zhang, M., Meng, Y. G., Kadkhodayan, M., Kirchhofer, D., Combs, D., and Damico, L. A., Albumin binding as a general strategy for improving the pharmacoki-netics of proteins. J. Biol. Chem., 277, 35035-35043 (2002).
16. Jiang, Z. Y., Gao, R., and Wang, Y. Q., Problems and solutions in PEGylation of protein and peptide drugs. Acta Pharm. Sin., 37, 396-400 (2002).
17. Yeh, P., Landais, D., Lemaitre, M., Maury, I., Crenne, J. Y., Becquart, J., Murry-Brelier, A., Boucher, F., Montay, G., Fleer, R., Hirel, P. H., Mayaux, J. F., and Klatzmann, D., Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate. Proc. Natl. Acad. Sci. USA, 89, 1904-1908 (1992).
18. Osborn, B. L., Olsen, H. S., Nardelli, B., Murray, J. H., Zhou, J. X., Garcia, A., Moody, G., Zaritskaya, L. S., and Sung, C, Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J. Pharmacol. Exp. Ther., 303, 540-548 (2002).
19. Melder, R. J., Osborn, B. L., Riccobene, T., Kanakaraj, P., Wei, P., Chen, G., Stolow, D., Halpern, W. G., Migone, T. S., Wang, Q., Grzegorzewski, K. J., and Gallant, G., Pharmacokinetics and its in vitro and its in vivo anti-tumor response of an interleukin- 2-human serum albumin fusion protein in mice. Cancer Immunol. Immunother., 54, 535-547 (2005).
20. Osborn, B. L., Sekut, L., Corcoran, M., Poortman, C, Sturm, B., Chen, G., Mather, D., Lin, H. L., and Parry, T. J., Albutropin: a growth hormone-albumin fusion with improved pharmacoki-netic and pharmacodynamics in rats and monkeys. Eur. J. Pharmacol, 456, 149-158 (2002).
21. Duttaroy, A., Kanakaraj, P., Osborn, B. L., Schneider, H., Pickeral, O. K., Chen, C, Zhang, G., Kaithamana, S., Singh, M., Schulingkamp, R., Crossan, D., Bock, J., Kaufman, T. E., Reavey, P., Carry-Barber, M., Krishnan, S. R., Garcia, A., Murphy, K., Siskind, J. K., Mclean, M. A., Cheng, S., Ruben, S., Birse, C. E., and Blondel, O., Development of a long-acting insulin analog using albumin fusion technology. Diabetes, 54, 251-258 (2005).
22. Chen, J., Bai, G., Cao, Y., Gao, Z., Zhang, Q., Zhu, Y., and Yang, W., One-step purification of a fusion protein of glucagon-like peptide-1 and human serum albumin expressed in pichia pastoris by an immunomagnetic separation technique. Biosci. Biotechnol. Biochem., 71, 2655-2662 (2007).
23. Tian, W., Li, Z. H., Cao, X. L., Yang, W. B., and Bai, G., Epitope maping of interfereon-a2b using a phage random peptide library. Chin. J. Microbiol. Immunol., 25, 578-582 (2005).
24. Laemmli, U. K., Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227, 680-685 (1970).
25. Merri, C. R., Goldman, D., Sedman, S., and Ebert, M. H., Ultrasensitive stain for proteins in polyacrylamide gels shows regional variation in cerebrospinal fluid proteins. Science, 211, 1437-1438 (1981).
26. Towbin, H., Staehelin, T., and Gordon, J., Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA, 76, 4350-4354 (1979).
27. Scrocchi, L. A., Brown, T. J., MacLusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., and Drucker, D. J., Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide a receptor gene. Nat. Med., 2, 1254-1258 (1996).
28. Chou, J. Z., Place, G. D., Waters, D. G., and Kirkwood, J., A radioimmunoassay for LY315902, an analog of glucagon-like insulinotropic peptide, and its application in the study of canine pharmacokinetics. J. Pharm. Sci, 86, 768-773 (1997).
29. Rolin, B., Larsen, M. O., Gotfredsen, C. F., Deacon, C. F., Carr, R. D., Wilken, M., and Knudsen, L. B., The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am. J. Physiol. Endocrinol. Metab., 283, E745-E752 (2002).
30. Harder, H., Nielsen, L., Tu, D. T., and Astrup, A., The effect of liraglutide, a long-acting glucagon-like peptide-1 derivative, on glycolic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care, 27, 1915-1921 (2004).
31. Kim, J. G., Baggio, L. L., Bridon, D. P., Castaigne, J. P., Robitaille, M. F., Jetté, L., Benquet, C, and Drucker, D. J., Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes, 52, 751-759 (2003).
32. Bloom, M., Block, J., Duttaroy, A., Grzegorzewski, K., Moor, P., Ou, Y., Wojcik, S., Zhou, X., and Bell, A., Albugon fusion protein: a long acting analogue of GLP-1 that provides lasting antidiabetic effect in animals. Diabetes, 52 (Suppl. 1), A112 (2003).
33. Dou, W. F., Lei, J. Y., Zhang, L. F., Xu, Z. H., Chen, Y., and Jin, J., Expression, purification, and characterization of re-combinant human serum albumin fusion protein with two human glucagon-like peptide-1 mutants in Pichia pastoris. Protein Expr. Purif., 61, 45-49 (2008).
34. Huang, J., Sakamuri, S., Leedom, T., Fu, Y. W., Oates, B., Desharnais, J., Tumelty, D., Del Rosario, J., Callans, S., Murphy, R., Lappe, R., Bradshaw, C, Woodnutt, G., and Levin, N., CVX-73: a GLP-1 mimetic CovX-Body (TM) with potent incretin bioactivity and extended pharmacokinetics in rodents and non-human primates. Diabetes, 56, A141 (2007).
35. Lee, S. H., Lee, S., Youn, Y. S., Na, D. H., Chae, S. Y., Byun, Y., and Lee, K. C, Synthesis characterization, and pharmaco-kinetic studies of PEGylated glucagons-like peptide-1. Bioconj. Chem., 6, 377-382 (2005).
36. Huang, Y. S., Chen, Z., Yang, Z. Y., Wang, T. Y., Zhou, L., Wu, J. B., and Zhou, L. F., Preparation and characterization of a potent, long-lasting recombinant human serum albumin-interferon-alpha2b fusion protein expressed in Pichia pastoris. Eur. J. Pharm. Biopharm., 67, 301-308 (2007).
37. Huang, Y. S., Chen, Z., Chen, Y. Q., Ma, G. C, Shan, J. F., Liu, W., and Zhou, L. F., Preparation and characterization of a novel exendin-4 human serum albumin fusion protein expressed in Pichia pastoris. J. Pept. Sci., 14, 588-595 (2008).
38. Peter, T. J., Serum albumin. Adv. Protein Chem., 37, 161-245 (1985).
39. Plamboeck, A., Hoist, J. J., Carr, R. D., and Deacon, C. F., Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetized pig. Diabetologia, 48, 1882-1890 (2005).
40. O'Harte, F. P., Mooney, M. H., Kelly, C. M., McKillop, A. M., and Flatt, P. R., Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1 (7-36)amide in obese diabetic ob/ob mice. Regul. Pept., 96, 95-104 (2001).